The Filing Desk

Gossamer Bio vs Q32 Bio

Gossamer Bio GOSS · Q32 Bio QTTB · Biotechnology

Q32 Bio reported revenue of $54 million in fiscal 2025, about the same as Gossamer Bio's $48 million in fiscal 2025. Gossamer Bio had an operating margin of -352.2%, against 31.4% at Q32 Bio. Free cash flow was −$171 million at Gossamer Bio and −$34 million at Q32 Bio.

Side by side

Gossamer BioQ32 Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$48M$54M
Revenue growth−57.7%—
Revenue growth a year, last 5 years—81.9%
Gross margin——
Operating margin−352.2%31.4%
Net margin−351.5%55.5%
Free cash flow−$171M−$34M
Free cash flow margin−353.5%−62.4%
Return on capital——
Net debt to EBITDA—−2.8x
Dividends and buybacks$0M$0M
Change in diluted share count1.0%27.5%
Last close$11.23$8.48
P/E at the last close—10.5×
Insider trades, last 12 months——
Piotroski F-score0 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Gossamer BioQ32 Bio
Operating margin
Percent of revenue
Gossamer BioQ32 Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gossamer BioQ32 Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gossamer Bio and Q32 Bio pages.